Home » Authors » Kim Coghill

Kim Coghill

Articles

ARTICLES

Sunesis In-Licenses Cancer Compound From Dainippon

Oct. 16, 2003

Favrille Raises $10.6M To Push NHL Product To Phase III Trial

Oct. 16, 2003

Favrille Raises $10.6M To Push NHL Product To Phase III Trial

Oct. 16, 2003

Sunesis In-Licenses Cancer Compound From Dainippon

Oct. 16, 2003

Dyax To Receive $35M Through Biotage Sale To Pyrosequencing

Oct. 15, 2003

Dyax To Receive $35M Through Biotage Sale To Pyrosequencing

Oct. 15, 2003

FDA Accepts ImClone's Erbitux Filing, Grants It Priority Review

Oct. 14, 2003

FDA Accepts ImClone's Erbitux Filing, Grants It Priority Review

Oct. 14, 2003

GPC Biotech Cutting Staff, Speeding Oncology Plans

Oct. 13, 2003

GPC Biotech Cutting Staff, Speeding Oncology Plans

Oct. 13, 2003

View All Articles by Kim Coghill

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...